Kornimate/medical-research-clean huggingface dataset:
abdominal pain management and point-of-care ultrasound in the emergency department

Conditions: Abdominal Pain

Summary: background: abdominal pain is one of the most common reasons for admission to the emergency department (ed). this study aimed to investigate the effect of point-of-care ultrasound (pocus) performed during the initial evaluation phase of patients who presented to the ed with abdominal pain on diagnostic processes, length of stay (los) in ed, and hospitalization and healthcare costs. methodology: this prospective, randomized, controlled, parallel group study was conducted with patients who presented to the sakarya education research hospital ed with abdominal pain from october 2019 to march 2020. patients were divided randomly into two groups: control group where standard diagnostic strategies were applied and the pocus group where pocus was performed together with standard diagnostic strategies. all data were analyzed using ibm spss 21.


Eligibility criteria:
inclusion criteria: * age \>18 years * patients who presented to the ed with abdominal pain * nontraumatic patients exclusion criteria: * permanent mental disability, * age \<18 years, * abdominal trauma within the last 24 hours, * pregnancy, morbid obesity, repeated admissions, * referral from an external center to the ed, * missing patient information.

Keywords: abdominal pain cost emergency department length of stay point-of-care ultrasound
evaluation of the basic assessment of severity of illness in children (basic) scale

Conditions: Acute Illness

Summary: the purpose of this study is to assess whether the basic scale--a simple, non-invasive clinical triage protocol--predicts severe illness, hospitalization or death among children under age five presenting for acute care in a rural african health center.


Eligibility criteria:
inclusion criteria: * child aged two months to five years presenting routine or urgent care in an ambulatory facility exclusion criteria: * none

Keywords: acute illnesses in children under five
timing of renal replacement therapy initiation in tumor lysis syndrome

Conditions: Renal Replacement Therapy for Acute Kidney Injury in ICU

Summary: the tenders study aims to evaluate the impact of the timing of renal replacement therapy (rrt) initiation on outcomes in patients with tumor lysis syndrome (tls) and associated acute kidney injury (aki). the study will compare early versus delayed rrt initiation, examining the effect on renal function at 30 days post-treatment.

tumor lysis syndrome (tls) is a common and life-threatening complication in patients with hematologic malignancies, characterized by severe metabolic imbalances due to rapid tumor cell destruction. this syndrome frequently leads to acute kidney injury (aki), requiring renal replacement therapy (rrt) in about 50% of cases. despite its clinical significance, there is a lack of consensus on the optimal timing of rrt initiation in tls-related aki. studies in other forms of aki suggest no difference in outcomes between early and delayed rrt initiation, but these results are not directly applicable to tls patients. this study seeks to fill this gap by analyzing the timing and outcomes of rrt initiation in tls patients. the retrospective study will collect data from multiple intensive care units (icus) across france. procedure: the study will retrospectively analyze patient data from 2013 to 2023, comparing early vs. delayed rrt initiation. follow-up: data on renal function, rrt usage, and mortality will be collected 30 days and one year after icu admission.

Eligibility criteria:
inclusion criteria: * adults aged ≥18 years. * hospitalized in the icu between january 1, 2013, and december 31, 2023. * diagnosed with a hematologic malignancy or solid tumor requiring chemotherapy. * diagnosed with tls based on the presence of two or more biochemical criteria (e.g., hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia) within 3 days before or 7 days after chemotherapy initiation. exclusion criteria: * patient or family opposition to data collection for research purposes. * incomplete medical records that preclude data extraction.

Keywords: tumoral lysis syndrome acute kidney injury renal replacement therapy, timing
application of auriculotherapy on nursing professional stress levels

Conditions: Stress

Summary: objectives: randomized controlled trial aimed to assess stress levels in nursing staff and review the auriculotherapy effectiveness through semi-permanent needles and seeds.

seventy five participants with average and high scores on the stress symptoms list (lss) were divided in 3 groups (control, needles and seeds). they were evaluated at the baseline, fourth and eighth sessions and 15-day follow-up and received 8 sessions through shenmen, kidney and brainstem points.

Eligibility criteria:
inclusion criteria: * average and high score by the list of stress symptoms * voluntary participation in the study * availability of time for submission to the sessions exclusion criteria: * pregnancy * medical license or vacation during the period * low score of stress

Keywords: stress
a study to investigate the effect of food, gender, and age on the pharmacokinetic profile of suvn-d4010 in healthy subjects

Conditions: Cognitive Disorder

Summary: the purpose of the study is to evaluate the effect of food, gender, and age on the single-dose pharmacokinetics (pk) of suvn-d4010.

the main objective of the study is to evaluate the safety and tolerability of orally administered suvn-d4010 under single-dose conditions in healthy adult male and female subjects and healthy elderly male subjects.

Eligibility criteria:
inclusion criteria: * healthy male subjects, aged 18 to 45 years, inclusive; healthy female subjects, aged 18 to 45 years, inclusive; healthy elderly male subjects, aged ≥65 years. * have a body mass index (bmi) between 18.0 and 30.0kg/m2 (inclusive) and weigh at least 50 kg and no more than 100 kg. exclusion criteria: * history or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. * any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the (first) administration of the study drug. * any positive result at screening for serum hepatitis b surface antigen, hepatitis c virus antibody, and human immunodeficiency virus antibody. * plasma or blood product donation within 1 month of the (first) administration of the study drug and any blood donation/blood loss more than 500 ml within the 2 months prior to the (first) administration of the study drug. * as judged by the investigator that the subject should not participate in the study if he/she is considered unlikely to comply with study procedures, restrictions, and requirements.

Keywords: serotonin 4 (5-ht4) receptor phase 1
magentum 1 heartmate 3 lvas: a single center prospective controlled study (magentum 1)

Conditions: Heart Failure; Cardiovascular Diseases

Summary: the purpose of this study is to obtain single-center safety and feasibility data on patients managed with reduced anti-coagulation, and the incidence of thrombotic and bleeding adverse events associated with the heartmate 3 lvas therapy.

patients with implanted heartmate 3 device will be bridged with heparin until target international normalized ratio (inr) of 2,0 - 3,0 will be reached on anticoagulation therapy with warfarin. along with warfarin, acetylsalicylic acid (asa) will be administered in dose of 100mg per day. enrollment for the study will take place in 1-6 weeks post implant of heartmate 3. low-intensity anticoagulation protocol will be started at 6 weeks after implant. target inr of 1,5-1,9 will be maintained and asa will be administered in dose of 100mg per day with adjustments based on verifynow testing. follow up will last for 12 months after heartmate 3 implantation. subsequently, the objectives of the study will be analyzed and evaluated.

Eligibility criteria:
inclusion criteria: * patients implanted with heartmate 3 lvas irrespective of an indication * data collection for major thrombophilic mutations including anti-phospholipid syndrome and lupus anticoagulant testing prior to low-intensity protocol anticoagulation initiation has been performed * patient will be compliant with an anticoagulation management in a judgment of the investigator * patient in stable condition with anticipated home discharge exclusion criteria: * absence of an informed consent * presence of additional mcs e.g. ecmo, rvad in less than 7 days prior to low- intensity protocol anticoagulation initiation * known history of major thrombotic event e.g. dvt * presence of other than biological valve prosthesis in aortic position * left atrial appendage in patients with atrial fibrillation or flutter not addressed by resection or exclusion at a time of the implant * hemodynamically significant or symptomatic carotid artery stenosis prior to low-intensity protocol anticoagulation initiation

Keywords: reduced anti-coagulation, mechanical circulatory support.
therapy of fifth metacarpal neck fractures - comparing functional treatment with reposition and finger splinting

Conditions: Boxer's Fracture

Summary: the purpose of this prospective randomized controlled clinical trial is to evaluate if functional treatment leads to a better functional outcome than a forearm cast and a finger splint in patients with fifth metacarpal neck fracture.

this study represents a prospective randomized clinical trial comparing two different conservative treatment options in patients with fifth metacarpal neck fracture. patients meeting the inclusion criteria will be enrolled in the present study provided they give their consent. informed written consent will be obtained. randomization will be performed according to the consort guidelines of prospective randomized trials using the software "randomizer" by the medical university of graz. patients allocated to the control group will receive a forearm cast with a finger splint in terms of an immobilizing treatment, while patients in the study group will receive buddy taping for fingers iv and v and an elastic bandage in terms of a functional treatment. both groups will receive the allocated bandage or splint for 4 weeks. the clinical outcome will be assessed 12 weeks after trauma.

Eligibility criteria:
inclusion criteria: * fifth metacarpal neck fractures * patient age between 18 and 70 years exclusion criteria: * palmar angulation \>50° in first lateral x-ray * pathologic fracture * intraarticular fracture * patients unable to consent * polytraumatized patients * pregnancy * compound fractures * multiple hand injuries * patients initially presenting more than 7 days after injury
the long-term impact of invasive meningococcal disease in australian adolescents and young adults

Conditions: Meningococcal Infections; Neisseria Meningitis Sepsis; Neisseria Infection

Summary: survivors of invasive meningococcal disease (imd) experience a range of mild to severe sequelae that impact upon their quality of life. the majority of studies to date have focused on the impact of imd on childhood and very little is known about the impact of the disease on adolescents and young people. the aim of this study is to assess the physical, neurocognitive, economic and societal impact of imd on adolescents and young adult australian survivors. hypothesis: 1. adolescents and young adult survivors who are 2 to 10 years post imd have significantly poorer outcomes including intellectual functioning and quality of life when compared to healthy controls. 2. imd imposes a significant financial burden upon individuals, families and society. 3. serogroup b disease is associated with an increased risk of sequelae when compared to non-b serogroup imd. study design: this a multi-centre, case-control mixed-methods study. survivors of imd (retrospective and prospective cases) and non-imd healthy controls will be invited to participate in the study. retrospective imd cases admitted in the previous 10 years will be identified through each of the participating hospitals (paediatric and adult hospitals). during the course of the study prospective recruitment of imd cases will also occur at participating hospitals. meningococcal foundations/groups will also be approached and asked to advertise and conduct a mail out to their members to inform them about the study. healthy controls will be prospectively recruited by "snowballing technique" whereby enrolled imd cases will be asked to distribute a study information sheet to their healthy friends/acquaintances who are approximately the same age. control participants may also be identified from databases at each participating site or through community advertising. enrolled cases will undergo a neurocognitive, psychological and physical examination 2 - 10 years post imd admission. a subset of imd cases will be invited to participate in a semi-structured interview. controls will also undergo neurocognitive, psychological and physical examination.


Eligibility criteria:
inclusion criteria: * patients aged 15 to 24 years 11 months at time of imd admission * hospitalised imd case from 1st january 2006 -with serogroup b or non-b imd, confirmed by culture or polymerase chain reaction (pcr) in blood or csf. * healthy controls aged 17 to 34 years 11 months at the time of assessment. exclusion criteria: * individuals who are not fluent with the english language. * control participants with a history of meningitis, encephalitis, or meningococcal disease, intellectual disability, intracranial pathology (eg. traumatic brain injury) that may impact on cognitive functioning, or significant vision and/or hearing loss that may impact on the validity or reliability of the neurocognitive assessment.
full spectrum vs. standard forward-viewing colonoscopy

Conditions: Colon Neoplasms

Summary: the aim of this study is to evaluate fuse-colonoscopy in terms of feasibility and its possible additive contribution in the detection of important lesions, namely polyps and cancers, compared to the standard "forward-viewing" approach, with and without the addition of the right-colon retroflexion technique, in a series of patients undergoing back-to-back screening or surveillance colonoscopies in a randomized fashion.

we changed the anticipated number of subjects enrollment for study: nct02117674 from 120 to 200 based on the following sample size estimation: tandem colonoscopies studies results, show that novel endoscopic technologies detect about 20% more adenomas than those conventional colonoscopy does (missed adenomas). since fuse colonoscopy cannot be considered as a perfect examination, we hypothesize that conventional colonoscopy will detect one third of the missed adenomas that fuse detects in a similar setting. therefore a sample size of 120 adenomas achieves 80% power to detect an odds ratio of 3.0 using a two-sided mcnemar test with a significance level of 0.05. the odds ratio is equivalent to a difference between two paired proportions of 14% which occurs when the proportion of detected missed adenomas during fuse is 21% and the proportion of missed adenomas during conventional colonoscopy is 7%. during one year period before the study initiation, our colonoscopy performance quality data show that we detect a mean number of adenomas per patient equal of 0.7 in a population similar to the one recruited in our study. therefore, 172 patients overall will be required to detect 120 adenomas. given the uncertainty of our estimation and in order to cope with patients exclusions, withdrawals and unexpected incomplete colonoscopies, we decided to recruit 200 patients. a more extensive description regarding the investigators study is provided in the following fields.

Eligibility criteria:
inclusion criteria: * adults undergoing elective screening or surveillance colonoscopy * symptomatic adults with indication for colonoscopy exclusion criteria: * age over 80 years * poor overall health (asa iii, iv) * recent abdominal surgery * presence of abdominal wall hernias * active colitis * multiple right colon diverticula * previous bowel resection * inflammatory bowel disease * polyposis syndromes

Keywords: colonoscopy adenoma detection rate full spectrum colonoscopy right colon retroflexion feasibility
use of rotem intraoperatively in women with placenta accreta

Conditions: Placenta Accreta

Summary: this study evaluates the use of rapid tests for hematocrit and clotting function in women undergoing surgery for placenta accreta. half of participants will have these rapid tests performed during surgery to guide blood product transfusion and the other half will have standard lab tests performed to guide transfusion.

placenta accreta has become an increasingly common pregnancy complication. serious complications are common in patients with placenta accreta, including hemorrhage, transfusion of blood products, abdominal organ injury, bladder surgery, and icu admission. hemorrhage, or excessive blood loss, is the most common complication and often results in impaired ability for the body to form blood clots normally. the development of rapid testing of hematocrit and clotting function may allow for earlier identification of patients who have severe blood loss and development of clotting abnormalities. the investigators are testing whether use of this technology in patients undergoing surgery for placenta accreta, with earlier identification of patients with severe blood loss or clotting abnormality, will result in a lower need for transfusion and fewer complications.

Eligibility criteria:
inclusion criteria: * women diagnosed with placenta accreta during pregnancy who are scheduled to have delivery by cesarean section with hysterectomy to follow. exclusion criteria: * non-english speaking

Keywords: thromboelastography
intravenous bibh 1 in patients with metastatic colorectal cancer

Conditions: Colorectal Neoplasms

Summary: study to evaluate the anti-tumour activity, safety and pharmacokinetics of unlabelled sibrotuzumab administered weekly (seven days +/- one day) at a dose of 100 mg (a total of 12 administrations) in patients with metastatic colorectal cancer.


Eligibility criteria:
inclusion criteria: * patients with metastatic colorectal cancer international union against cancer (uicc) stage iv who are progressive under at least two previous chemotherapy regimes or who refused conventional treatment or who are not eligible for conventional treatment * progressive disease documented by subsequent computed tomography (ct) or magnetic resonance imaging (mri) scanning prior to study entry. the last ct or mri scans must be performed within 1 month before study entry. the first ct or mri scan should be conducted within 6 months before study entry * eastern cooperative oncology group (ecog) performance status of ≤ 2 * expected survival of ≥ 6 months * greater than or equal to 18 years of age * platelet count ≥ 100 x 10\*\*9/l * total leukocytes ≥ 2500/mm\*\*3 * alanine aminotransferase/aspartate aminotransferase (alt/ast) ≤ 4 x upper limit of normal * total bilirubin ≤ 2.0 mg/dl (or 34µmol/l, systeme international (si) unit equivalent) * serum creatinine ≤ 2.0 mg/dl (0.20 mmol/l) * written informed consent in accordance with good clinical practice and local legislation exclusion criteria: * active metastatic disease to the central nervous system, exhibited by new or enlarging lesions on ct or mri scan or within 3 months of treatment (i.e., surgery or radiotherapy) for brain metastases * exposure to an investigation agent within 30 days prior to the first bibh 1 infusion * patients who are not fully recovered from surgery (incomplete healing) * chemotherapy or immunotherapy within 30 days prior to the first bibh 1 infusion * radiation therapy to the symptomatic sites included for tumour measurements within 30 days prior to study entry * previous administration of a murine, chimeric or humanised measurement and/or antibody fragment (e.g. bibh 1, panorex) * serious illness: e.g., active infections requiring antibiotics, bleeding disorders, patients with known untreated or unstable coronary heart disease (e.g. unstable angina or myocardial infarction within 6 months prior to study entry) or diseases considered by the investigator to have potential for interfering with obtaining accurate results from this study * women who are breast-feeding or pregnant * men and women of childbearing potential who are unwilling to utilise a medically acceptable method of contraception * patients who suffer from autoimmune diseases
attentional focus and prefrontal cortical activation in older adults and patients with parkinson's disease (pd)

Conditions: Parkinson Disease

Summary: attention may influence the motor performance and frontal activity. this study will examine the effect of different attentional focus: internal, external and divided attention (dual task) on prefrontal cortical activation (fnirs) and on gait performance. thirty older adults and thirty pd will participate in this study.

the subjects will be guided to walk at a normal pace while maintaining the required attentional focus. subjects will walk on 20 m four times in each of the four different focus conditions : 1. no instructions about the attentional focus 2. internal focus on their feet movements, 3. external focus on two lines drawn on the floor, 4. divided attention (walking while performing an arithmetic task). a fnirs system will be used for the prefrontal cortex activation evaluation and feetme soles for gait analyses.

Eligibility criteria:
inclusion criteria: * for 2 groups : * man or woman 60-85 years old * informed consent obtained * group parkinson : clinical diagnosis of idiopathic parkinson's disease, according to the uk brain bank criteria. exclusion criteria: * for 2 groups : * assisted walker * neurological (other than those resulting from parkinson's disease), cardiologic, rheumatologic disorders * disorders affecting gait. * montreal cognitive assessment (moca) \< 24. * concomitant medication likely to interfere with the results. * group parkinson: * freezing * hoehn et yahr \> iii

Keywords: attention nirs gait prefrontal cortex parkinson's disease
complications of enterocystoplasty in children

Conditions: Complications of Surgical Procedure; Neurogenic Bladder; Spina Bifida; Child, Only

Summary: the goal of this observational study is to describe the complications in participants who underwent enterocystoplasty in childhood. the main question\[s\] it aims to answer are: * what kind of complications are there * the kind of complications depending on the type of enterocystoplasty participants data will be collected in the medical field. there is no comparison group.

from 1982 to 2020, all patients who had an enterocystoplasty in childhood were collected. complications were numbered depending on the type of enterocystoplasty and the investigators tried to find which risk factors exist.

Eligibility criteria:
inclusion criteria: * patients who underwent a enterocystoplasty before 18 years old exclusion criteria: * patients who underwent a enterocystoplasty after 18 years old

Keywords: augmentation enterocystoplasty surgical complications children retrospective study